Precision in Progress: The Role of MDT and Genetic Testing in Advanced PCa скачать в хорошем качестве

Precision in Progress: The Role of MDT and Genetic Testing in Advanced PCa

A regional roundtable discussion, moderated by Jason Hafron, MD, Michigan Institute of Urology, focused on the diagnostic and treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Hafron was joined by other Michigan Institute of Urology providers, including Kenneth M. Kernen, MD; J. Rene Frontera, MD; and Joshua Palka, DO. In the fifth segment of the roundtable, the panel breaks down the growing role of MDT and the evolving use of radiation in oligometastatic disease. They also share their approaches to treating the primary tumor and metastatic sites, highlighting data from the STAMPEDE trial and personal clinical experience.